The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
After finishing at $5.15 in the prior trading day, Alzamend Neuro Inc (NASDAQ: ALZN) closed at $4.18, down -18.83%. In other words, the price has decreased by -$18.83 from its previous closing price. On the day, 5.77 million shares were traded.
Ratios:
Our goal is to gain a better understanding of ALZN by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.44 and its Current Ratio is at 5.44. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Ascendiant Capital Markets on October 01, 2021, initiated with a Buy rating and assigned the stock a target price of $8.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 12 ’25 when Hyperscale Data, Inc. bought 516,090 shares for $0.54 per share.
Horne William B. bought 3,334 shares of ALZN for $3,285 on Mar 26 ’25. The Director now owns 30,000 shares after completing the transaction at $0.99 per share. On Mar 21 ’25, another insider, AULT MILTON C III, who serves as the Director of the company, bought 2,905 shares for $1.02 each. As a result, the insider paid 2,969 and bolstered with 85,273 shares of the company.
Stock Price History:
Over the past 52 weeks, ALZN has reached a high of $135.54, while it has fallen to a 52-week low of $4.59. The 50-Day Moving Average of the stock is -40.92%, while the 200-Day Moving Average is calculated to be -67.83%.
Shares Statistics:
A total of 0.80M shares are outstanding, with a floating share count of 0.70M. Insiders hold about 12.38% of the company’s shares, while institutions hold 14.15% stake in the company.
Earnings Estimates
A comprehensive evaluation of Alzamend Neuro Inc (ALZN) is underway, with the input of 1.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$3.69, with high estimates of -$3.69 and low estimates of -$3.69.
Analysts are recommending an EPS of between -$11.88 and -$11.88 for the fiscal current year, implying an average EPS of -$11.88. EPS for the following year is -$10.98, with 2.0 analysts recommending between -$6.75 and -$15.21.
